Browse All : Market Research Reports
Introduction
The prevalence of neuropathic pain is estimated at approximately 10% in the adult population of the US, and is likely to be the same in other developed countries. Peripheral neuropathic pain is a common co-morbidity in HIV, diabetes, and herpes zoster; it affects approximately 22% of HIV-positive individuals, 6% of type 1 diabetics, 18% of type 2 diabetics, and 6–18% of herpes zoster cases.
Features and benefits:
Gain insight into market potential, including a robust 10-year epidemiology forecast of neuropathic pain cases in HIV, diabetes, and herpes zoster.
Understand the key epidemiologic risk factors associated with peripheral neuropathic pain in HIV, diabetes, and herpes zoster.
Highlights
During 2010, Datamonitor estimates that 239,700 diagnosed, prevalent HIV cases with peripheral neuropathic pain existed in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Between 2010 and 2020, Datamonitor forecasts these cases to increase by 17% in the seven major markets, resulting in 279,900 cases in 2020.
Among the diagnosed diabetic population in 2010, Datamonitor estimates that 128,500 and 5.59 million prevalent types 1 and 2 diabetes cases with diabetic peripheral neuropathic pain (DPNP), respectively, existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts both diabetes types 1 and 2 DPNP cases to increase by 14%.
During 2010, Datamonitor estimates that 249,000 diagnosed, incident post-herpetic neuralgia cases existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts these cases to increase by 16% in the seven major markets, resulting in 288,000 cases in 2020.
Table Of Contents
OVERVIEW
Catalyst
Summary
Catalyst
Summary
EXECUTIVE SUMMARY
Disease burden overview
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Forecast results, 2010–20
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Disease burden overview
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Forecast results, 2010–20
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
Etiological descriptions of peripheral neuropathic pain
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Diagnosis of and testing for peripheral neuropathic pain in HIV
Diagnosis of and testing for peripheral neuropathic pain in diabetes
Diagnosis of and testing for post-herpetic neuralgia
Classification of peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Etiological descriptions of peripheral neuropathic pain
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Diagnosis of and testing for peripheral neuropathic pain in HIV
Diagnosis of and testing for peripheral neuropathic pain in diabetes
Diagnosis of and testing for post-herpetic neuralgia
Classification of peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
GLOBAL VARIATION AND HISTORICAL TRENDS
Global variation and historical trends
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
Global variation and historical trends
Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes
Post-herpetic neuralgia
DRIVERS OF DISEASE EPIDEMIOLOGY
Risk factors for peripheral neuropathic pain in HIV/AIDS
Nucleoside reverse transcriptase inhibitors
HIV positivity time length and AIDS status
Age
Gender
Risk factors for peripheral neuropathic pain in diabetes
Disease duration
Age
Diabetes type
HDL cholesterol
Risk factors for post-herpetic neuralgia
Age
Gender
Immunologically compromised status
Co-morbid conditions
Peripheral neuropathic pain in diabetes
Risk factors for peripheral neuropathic pain in HIV/AIDS
Nucleoside reverse transcriptase inhibitors
HIV positivity time length and AIDS status
Age
Gender
Risk factors for peripheral neuropathic pain in diabetes
Disease duration
Age
Diabetes type
HDL cholesterol
Risk factors for post-herpetic neuralgia
Age
Gender
Immunologically compromised status
Co-morbid conditions
Peripheral neuropathic pain in diabetes
EPIDEMIOLOGIC FORECASTING OF PERIPHERAL NEUROPATHIC PAIN
Overview
Population denominators
Subpopulations
Diabetic peripheral neuropathic pain
Post-herpetic neuralgia
US
Sources used
Methods
Sources not used
Japan
Sources used
Methods
Sources not used
France
Sources used
Methods
Sources not used
Germany
Sources used
Methods
Sources not used
Italy
Sources used
Methods
Sources not used
Spain
Sources used
Methods
Sources not used
UK
Sources used
Methods
Sources not used
Overview
Population denominators
Subpopulations
Diabetic peripheral neuropathic pain
Post-herpetic neuralgia
US
Sources used
Methods
Sources not used
Japan
Sources used
Methods
Sources not used
France
Sources used
Methods
Sources not used
Germany
Sources used
Methods
Sources not used
Italy
Sources used
Methods
Sources not used
Spain
Sources used
Methods
Sources not used
UK
Sources used
Methods
Sources not used
EPIDEMIOLOGIC RESULTS
Estimated diagnosed, prevalent cases of HIV with peripheral neuropathic pain and future trends
Age and gender segmentation
Age-standardized prevalent (and/or incident) rates
Estimated diagnosed, prevalent cases of diabetes types 1 and 2 with peripheral neuropathic pain and future trends
Age and gender segmentation
Age-standardized prevalent (and/or incident) rates
Estimated diagnosed, incident post-herpetic neuralgia cases and future trends
Segmentation by age group
Segmentation by gender
Age and gender segmentation
Age-standardized prevalent (and/or incident) rates
Estimated diagnosed, prevalent cases of diabetes types 1 and 2 with peripheral neuropathic pain and future trends
Age and gender segmentation
Age-standardized prevalent (and/or incident) rates
Estimated diagnosed, incident post-herpetic neuralgia cases and future trends
Segmentation by age group
Segmentation by gender
DISCUSSION
Peripheral neuropathic pain in HIV
Strengths and limits of Datamonitor’s epidemiologic projections
Peripheral neuropathic pain in diabetes
Strengths and limits of Datamonitor’s epidemiologic projections
Post-herpetic neuralgia
Strengths and limits of Datamonitor’s epidemiologic projections
Peripheral neuropathic pain in HIV
Strengths and limits of Datamonitor’s epidemiologic projections
Peripheral neuropathic pain in diabetes
Strengths and limits of Datamonitor’s epidemiologic projections
Post-herpetic neuralgia
Strengths and limits of Datamonitor’s epidemiologic projections
LIST OF TABLES
Table: International Association for the Study of Pain taxonomy for pain conditions
Table: Key aspects in diagnosing peripheral neuropathic pain in diabetes
Table: ICD-10 codes relevant to peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia
Table: Classification systems for diabetic neuropathies
Table: Neuropathic pain prevalence according to population-based studies
Table: Peripheral neuropathy and neuropathic pain prevalence among HIV cases
Table: Peripheral neuropathy and neuropathic pain prevalence among diabetes cases
Table: Herpes zoster and post-herpetic neuralgia burden in various countries
Table: HIV and AIDS data sources in the seven major markets used in this analysis
Table: Summary of sources used in analyses of type 2 diabetes mellitus, published between 1999 and 2009
Table: Diagnosed prevalent cases of HIV with peripheral neuropathic pain across all ages in the seven major markets, 2010–20
Table: Diagnosed prevalent cases of type 1 diabetes with peripheral neuropathic pain in those aged 20–79 in the seven major markets, 2010–20
Table: Diagnosed prevalent cases of type 2 diabetes with peripheral neuropathic pain in those aged 20–79 in the seven major markets (000s), 2010–20
Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, 2010–20
Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, segmented by age group, 2010–20
Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, segmented by gender, 2010–20
LIST OF FIGURES
Figure: Age-adjusted post-herpetic neuralgia incidence in men at least 20 years of age (per 100,000), 2010
Figure: Age-adjusted post-herpetic neuralgia incidence in women at least 20 years of age (per 100,000), 2010
Table: International Association for the Study of Pain taxonomy for pain conditions
Table: Key aspects in diagnosing peripheral neuropathic pain in diabetes
Table: ICD-10 codes relevant to peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia
Table: Classification systems for diabetic neuropathies
Table: Neuropathic pain prevalence according to population-based studies
Table: Peripheral neuropathy and neuropathic pain prevalence among HIV cases
Table: Peripheral neuropathy and neuropathic pain prevalence among diabetes cases
Table: Herpes zoster and post-herpetic neuralgia burden in various countries
Table: HIV and AIDS data sources in the seven major markets used in this analysis
Table: Summary of sources used in analyses of type 2 diabetes mellitus, published between 1999 and 2009
Table: Diagnosed prevalent cases of HIV with peripheral neuropathic pain across all ages in the seven major markets, 2010–20
Table: Diagnosed prevalent cases of type 1 diabetes with peripheral neuropathic pain in those aged 20–79 in the seven major markets, 2010–20
Table: Diagnosed prevalent cases of type 2 diabetes with peripheral neuropathic pain in those aged 20–79 in the seven major markets (000s), 2010–20
Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, 2010–20
Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, segmented by age group, 2010–20
Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, segmented by gender, 2010–20
LIST OF FIGURES
Figure: Age-adjusted post-herpetic neuralgia incidence in men at least 20 years of age (per 100,000), 2010
Figure: Age-adjusted post-herpetic neuralgia incidence in women at least 20 years of age (per 100,000), 2010
Related Market Research Reports:
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
Visit Our Blog : Market Research Reports
No comments:
Post a Comment